ClinicalTrials.Veeva

Menu

Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient (BIOCOVU)

U

University Hospital, Lille

Status

Completed

Conditions

COVID-19
Infection Viral
Coronavirus

Study type

Observational

Funder types

Other

Identifiers

NCT04341792
2020_33
2020-A00906-33 (Other Identifier)

Details and patient eligibility

About

There is no predictive tool for patients admitted to the emergency department with a suspicion of Covid-19 that will worsen secondarily and require a heavy lifting.

In a context of saturation of the healthcare system by the pandemic at Covid-19,it is essential to identify specific, accessible prognostic markers via minimally invasive sampling with low risk of infection for personnel caregiver, for optimal allocation of resuscitation resources.

This study proposes to evaluate the biological markers of routine care known to be associated with resuscitation admission in relation to hospitalization on conventional service for the prediction of worsening of patients admitted to the emergencies for Covid-19.

Enrollment

373 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical criteria for suspicion of Covid-19 in an epidemic period
  • Consultation in the emergency departement
  • Non-opposition agree

Exclusion criteria

  • impairment related to another identified cause than Covid-19, in particular a rapid diagnostic test flu-positive
  • Severe patient from the outset with transfer to intensive care within 12 hours of admission to the Emergency Department
  • No social security coverage (beneficiary or entitled person)
  • Poor understanding of French
  • Refusal to participate

Trial contacts and locations

1

Loading...

Central trial contact

Delphine Garrigue, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems